Evaluation of TGFβ1 receptor transcript levels showed significantly reduced TGFβR2 expression, which probably hamper tumor suppressive effect of TGFβ1 in CML patients. The gene discussed is TGFB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.